{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:20:09Z","timestamp":1762507209416,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.urolonc.2017.10.005","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T02:30:38Z","timestamp":1509503438000},"page":"77.e15-77.e21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Gu\u00e9rin therapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Naoya","family":"Niwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-4958","authenticated-orcid":false,"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.10.005_bib1","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.10.005_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib3","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.6004\/jnccn.2016.0131","article-title":"NCCN guidelines insights: bladder cancer, version 2.2016","volume":"14","author":"Clark","year":"2016","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.urolonc.2017.10.005_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib8","doi-asserted-by":"crossref","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.urolonc.2017.10.005_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2003.09.018","article-title":"Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis","volume":"45","author":"Lopez-Beltran","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.7883\/yoken.JJID.2007.331","article-title":"Historical review of BCG vaccine in Japan","volume":"60","author":"Yamamoto","year":"2007","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.urolonc.2017.10.005_bib12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.urology.2008.12.039","article-title":"Discontinuance of bacille Calmette-Gu\u00e9rin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence","volume":"73","author":"Takeda","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.10.005_bib13","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib14","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib15","doi-asserted-by":"crossref","first-page":"e1001012","DOI":"10.1371\/journal.pmed.1001012","article-title":"The BCG world atlas: a database of global BCG vaccination policies and practices","volume":"8","author":"Zwerling","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2017.10.005_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(01)66427-9","article-title":"Intravesical versus intravesical plus intradermal bacillus Calmette-Gu\u00e9rin: a prospective randomized study in patients with recurrent superficial bladder tumors","volume":"155","author":"L\u00fcftenegger","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib18","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.ju.0000059681.67567.12","article-title":"The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin","volume":"169","author":"Bilen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0069892","article-title":"Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis","volume":"8","author":"Els\u00e4\u00dfer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2017.10.005_bib20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/thorax.57.9.804","article-title":"A meta-analysis of the effect of bacille Calmette Gu\u00e9rin vaccination on tuberculin skin test measurements","volume":"57","author":"Wang","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.urolonc.2017.10.005_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Gu\u00e9rin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2014different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.urolonc.2017.10.005_bib24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Gu\u00e9rin substrains","volume":"189","author":"Secanella-Fandos","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2013.05.027","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence","volume":"64","author":"Ehdaie","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.10.005_bib26","first-page":"853","article-title":"Comparison of erythema and induration as results of tuberculin tests","volume":"9","author":"Kimura","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.urolonc.2017.10.005_bib27","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1001\/jama.293.22.2756","article-title":"Discrepancy between the tuberculin skin test and the whole-blood interferon assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country","volume":"293","author":"Kang","year":"2005","journal-title":"J Am Med Assoc"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917305355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917305355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:12:34Z","timestamp":1761041554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917305355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1078143917305355"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.10.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Gu\u00e9rin therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}